Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruixiang Luo

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Clinical Laboratory|June 15, 2022
Prevalence and Antimicrobial Resistance of Ureaplasma urealyticum and Mycoplasma hominis in Patients with Genital Tract Infection in Jiangsu, ChinaRuixiang Luo, Kang Xun, Lingli Zuo, et al.
Journal of Medicinal Chemistry|June 27, 2025
LC-MF-4, a Novel FGFR3 Degrader for Therapeutic Intervention in FGFR3-Altered CancersLulu Zheng, Jiaqi Cao, Lin Ma, et al.
Molecular Diversity|October 14, 2024
Anti-inflammatory effects of resveratrol in treating interstitial cystitis/bladder pain syndrome: a multi-faceted approach integrating network pharmacology, molecular docking, and experimental validationWenshuang Li, Ruixiang Luo, Zheng Liu, et al.
Polymers|March 14, 2026
Deformation Behavior and Accuracy Control in Gas-Assisted Diaphragm Forming of Composites Using Multi-Point Flexible DieDeyu Yue, Ruixiang Luo, Yuan Li, et al.
Communications Biology|May 8, 2026
Targeting CCR1-mediated macrophage phenotypic switching to alleviate bladder pain and urinary dysfunction in interstitial cystitisRuixiang Luo, Wenshuang Li, Bolong Liu, et al.
European Journal of Medicinal Chemistry|May 17, 2025
Discovery of LC-SF-14, a selective dual inhibitor of SHP2 and FGFR for the treatment of FGFR2-driven gastric cancerLei Zheng, Yuhan Wang, Zheng Jiang, et al.
Journal of Medicinal Chemistry|May 23, 2023
Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric CancerLin Ma, Yingying Li, Ruixiang Luo, et al.
EMBO Reports|August 22, 2022
eEF2 in the prefrontal cortex promotes excitatory synaptic transmission and social novelty behaviorXuanyue Ma, Liuren Li, Ziming Li, et al.
Bioorganic Chemistry|February 23, 2024
Discovery of a doublecortin-like kinase 1 inhibitor to prevent inflammatory responses in acute lung injuryBinhao Cai, Ying Xu, Ruixiang Luo, et al.
Journal of Medicinal Chemistry|May 9, 2024
Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory DiseasesLingfeng Chen, Ruixiang Luo, Lin Ma, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Clinical Laboratory|June 15, 2022
Prevalence and Antimicrobial Resistance of Ureaplasma urealyticum and Mycoplasma hominis in Patients with Genital Tract Infection in Jiangsu, ChinaRuixiang Luo, Kang Xun, Lingli Zuo, et al.
Journal of Medicinal Chemistry|June 27, 2025
LC-MF-4, a Novel FGFR3 Degrader for Therapeutic Intervention in FGFR3-Altered CancersLulu Zheng, Jiaqi Cao, Lin Ma, et al.
Molecular Diversity|October 14, 2024
Anti-inflammatory effects of resveratrol in treating interstitial cystitis/bladder pain syndrome: a multi-faceted approach integrating network pharmacology, molecular docking, and experimental validationWenshuang Li, Ruixiang Luo, Zheng Liu, et al.
Polymers|March 14, 2026
Deformation Behavior and Accuracy Control in Gas-Assisted Diaphragm Forming of Composites Using Multi-Point Flexible DieDeyu Yue, Ruixiang Luo, Yuan Li, et al.
Communications Biology|May 8, 2026
Targeting CCR1-mediated macrophage phenotypic switching to alleviate bladder pain and urinary dysfunction in interstitial cystitisRuixiang Luo, Wenshuang Li, Bolong Liu, et al.
European Journal of Medicinal Chemistry|May 17, 2025
Discovery of LC-SF-14, a selective dual inhibitor of SHP2 and FGFR for the treatment of FGFR2-driven gastric cancerLei Zheng, Yuhan Wang, Zheng Jiang, et al.
Journal of Medicinal Chemistry|May 23, 2023
Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric CancerLin Ma, Yingying Li, Ruixiang Luo, et al.
EMBO Reports|August 22, 2022
eEF2 in the prefrontal cortex promotes excitatory synaptic transmission and social novelty behaviorXuanyue Ma, Liuren Li, Ziming Li, et al.
Bioorganic Chemistry|February 23, 2024
Discovery of a doublecortin-like kinase 1 inhibitor to prevent inflammatory responses in acute lung injuryBinhao Cai, Ying Xu, Ruixiang Luo, et al.
Journal of Medicinal Chemistry|May 9, 2024
Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory DiseasesLingfeng Chen, Ruixiang Luo, Lin Ma, et al.
Pageof 4